TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06419205: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Sponsor: Akebia Therapeutics · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$931,500

Rescue Site Savings

+$621,000

Unlock Full NCT06419205 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06419205 Rescue Dossier →